SCHEMBL4493394

SCHEMBL4493394

Cc1[nH]c(C)c(-c2c[nH]c(-c3cccc(C(F)(F)F)c3)cc2=O)c(=O)c1Br

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC2A1 P11166 1/20 0.52
SLC11A2 P49281 1/20 0.38
IKBKB O14920 1/20 0.37
PIN1 Q13526 1/20 0.37
SCN2A Q99250 3/20 0.37
CDC7 O00311 1/20 0.37
MAPT P10636 1/20 0.37
XDH P47989 1/20 0.37
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
HTT P42858 1/20 0.36
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
PARP10 Q53GL7 1/20 0.35
PARP11 Q9NR21 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4483281 0.89 SLC2A1 (0.44) SLC2A1IKBKB
SCHEMBL4472791 0.89 SLC2A1 (0.46) SLC2A1SLC11A2MAPTALDH1A1SMN1; SMN2
SCHEMBL4492022 0.87 MAPT (0.41) SLC2A1SLC11A2IKBKBPIN1SCN2A
SCHEMBL4490476 0.84 SLC2A1 (0.38) SLC2A1CDC7MAPTKDM4EALDH1A1
SCHEMBL4484311 0.84 BRD4 (0.38) SLC2A1MAPTMEN1HTTKMT2A
SCHEMBL4486777 0.84 SCN2A (0.40) SLC11A2IKBKBPIN1SCN2ACDC7
SCHEMBL4476392 0.83 SLC2A1 (0.43) SLC2A1MAPT
SCHEMBL4475104 0.82 SLC2A1 (0.40) SLC2A1IKBKB
SCHEMBL4478994 0.81 SLC2A1 (0.55) SLC2A1BRD4
SCHEMBL4464654 0.81 ADORA2A (0.39) SLC2A1MAPTKDM4EMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US claimed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US claimed
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US disclosed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
EP-1858876-A2 PYRIDINONE DERIVATIVES AGAINST MALARIA GLAXO GROUP LIMITED (GB) 2007-11-28 EP disclosed
WO-2006094799-A2 PYRIDINONE DERIVATIVES AGAINST MALARIA GLAXO GROUP LIMITED (GB) 2006-09-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287461-A1 Pyridinone Derivatives Against Malaria G6PD, PNPO, PLPBP SLC2A1 2278/4885SLC11A2 1320/4885IKBKB 3664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.